BXL628, a novel vitamin d3 analog arrests prostate growth in patients with benign prostatic hyperplasia: A randomized clinical trial

European Urology

Volumn 49, Issue 1, 2006, Pages 82-86

  Colli, Enrico ^a   Rigatti, Patrizio ^b,h   Montorsi, Francesco ^b   Artibani, Walter ^c   Petta, Stefano ^d   Mondaini, Nicola ^e   Scarpa, Roberto ^f   Usai, Paolo ^g   Olivieri, Lorenza ^a   Maggi, Mario ^e   Belgrano, E ⁱ   Carini, M ^j   Catanzaro, F ^k   Mirone, V ^l   Petta, S ^m   Rizzo, M ^e   Scarpa, R ^f   Usai, E ^g   Zucconelli, R ⁿ  

^a BioXell SpA   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f SAN LUIGI GONZAGA HOSPITAL   (Italy)

^g SS Trinit Hospital   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF TRIESTE   (Italy)

^j SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^k IRCCS MULTIMEDICA   (Italy)

^l UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^m SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁿ San Tommaso dei Battuti Hospital   (Italy)

more..

Author keywords

BXL628; Prostate; Vitamin D3

Indexed keywords

ANDROSTANOLONE; BXL 628; COLECALCIFEROL DERIVATIVE; LUTEINIZING HORMONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HORMONE BLOOD LEVEL; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PELVIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TESTOSTERONE BLOOD LEVEL; UROFLOWMETRY;

EID: 29044445300     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.08.014     Document Type: Article

References (17)

1. D.M. Weiner, R. McDaiel, and F.C. Lowe Urologic manpower issues for the 21st century: assessing the impact of changing population dynamics Urology 49 1997 335 342
2. A.M. Williams, I. Simon, P.K. Landis, C. Moser, W. Christens-Barry, and H.B. Carter Prostatic growth rate determined from MRI data: age-related longitudinal changes J Androl 20 1999 474 480
3. J.B. Anderson, C.G. Roehrborn, J.A. Schalken, and M. Emberton The progression of benign prostatic hyperplasia: examining the evidence and determining the risk Eur Urol 39 2001 390 399
4. C.R. Chapple Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician BJU Int 94 9 2004 1399
5. C.L. Foley, S.R. Bott, I.S. Shergill, and R.S. Kirby An update on the use of 5alpha-reductase inhibitors Drug Today (Barc) 40 3 2004 213 223
6. J.D. McConnell, C.G. Roehrborn, O.M. Bautista, G.L. Andriole Jr., C.M. Dixon, J.W. Kusek Medical Therapy of Prostatic Symptoms (MTOPS) Research Group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398
7. D.J. Carbone Jr., and S. Hodges Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life Int J Impot Res 15 4 2003 299 306
8. D.M. Peehl, R.J. Skowronski, G.K. Leung, S.T. Wong, T.A. Stamey, and D. Feldman Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells Cancer Res 54 1994 805 810
9. M. Kivineva, M. Blauer, H. Syvala, T. Tammela, and P. Tuohimaa Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate J Steroid Biochem Mol Biol 66 1998 121 127
10. C. Crescioli, M. Maggi, G.B. Vannelli, M. Luconi, R. Salerno, and T. Barni Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia J Clin Endocrinol Metab 85 2000 2576 2583
11. S.E. Tong, M.A. Bolognese, S.B. Cohen, J.C. Gallagher, S.T. Harris, and S.L. Silverman Therapeutic effects in postmenopausal, osteoporotic (PMOP) women of a vitamin D analog, Ro-26-9228, with minimal effects on calcium (Ca) homeostatis J Bone Miner Res 15 Suppl. 1 2000 S562
12. C. Crescioli, P. Ferruzzi, A. Caporali, M. Scaltriti, S. Bettuzzi, and R. Mancina Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia Eur J Endocrinol 150 2004 591 603
13. H. Hricak, R.B. Jeffrey, G.C. Dooms, and E.A. Tanagho Evaluation of prostate size: comparison of ultrasound and magnetic resonance imaging Urol Radiol 9 1 1987 1 8
14. A. Rahmouni, A. Yang, C.M. Tempany, T. Frenkel, J. Epstein, and P. Walsh Accuracy of in-vivo assessment of prostatic volume by MRI and transrectal ultrasonography J Comput Assist Tomogr 16 6 1992 Nov-Dec 935 940
15. R.G. Aaenink Formula-derived prostate volume determination Eur Urol 29 1996 399 402
16. J.D. McConnell, R. Bruskewitz, P. Walsh, G. Andriole, M. Lieber, and H.L. Holtgrewe The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia N Engl J Med 338 1998 557 563
17. E. Stoner The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The finasteride Study Group J Urol 147 1992 1298 1302